Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic Colonization and Induces Cytotoxic Autophagy in Breast Cancer.
Kozyreva VK, Kiseleva AA, Ice RJ, Jones BC, Loskutov YV, Matalkah F, Smolkin MB, Marinak K, Livengood RH, Salkeni MA, Wen S, Hazard HW, Layne GP, Walsh CM, Cantrell PS, Kilby GW, Mahavadi S, Shah N, Pugacheva EN. Kozyreva VK, et al. Among authors: salkeni ma. Mol Cancer Ther. 2016 Aug;15(8):1809-22. doi: 10.1158/1535-7163.MCT-15-0688. Epub 2016 May 27. Mol Cancer Ther. 2016. PMID: 27235164 Free PMC article.
Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K. Vahdat LT, et al. Among authors: salkeni ma. Oncologist. 2017 Mar;22(3):245-254. doi: 10.1634/theoncologist.2016-0265. Epub 2017 Feb 20. Oncologist. 2017. PMID: 28220020 Free PMC article. Clinical Trial.
The Stem Cell Phenotype of Aggressive Breast Cancer Cells.
Margaryan NV, Hazard-Jenkins H, Salkeni MA, Smolkin MB, Coad JA, Wen S, Seftor EA, Seftor REB, Hendrix MJC. Margaryan NV, et al. Among authors: salkeni ma. Cancers (Basel). 2019 Mar 8;11(3):340. doi: 10.3390/cancers11030340. Cancers (Basel). 2019. PMID: 30857267 Free PMC article.
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F, Awada A, Canon JL, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Vincent S, Bahamon B, Galinsky KJ, Patel C, Neuwirth R, Leonard EJ, Diamond JR. Lim B, et al. Among authors: salkeni ma. Clin Cancer Res. 2021 Jun 15;27(12):3329-3338. doi: 10.1158/1078-0432.CCR-20-4131. Epub 2021 Apr 5. Clin Cancer Res. 2021. PMID: 33820779
23 results